Browsing by Author "Kurada, Satya"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Cognitive Impairment and Insomnia in Celiac Disease: A Systematic Review and Meta-Analysis
    (Korean Society of Gastroenterology, 2024) Beas, Renato; Godoy, Ambar; Norwood, Dalton A.; Ascencio, Ysaith Orellana; Izquierdo-Veraza, Diego; Montalvan-Sanchez, Eleazar E.; Ramirez, Mirian; Kurada, Satya; Medicine, School of Medicine
    Emerging evidence suggests a broader spectrum of celiac disease (CeD) system involvement, including neurological manifestations. We aimed to conduct a systematic review and meta-analysis of the available evidence from studies assessing the association of cognitive impairment and insomnia with CeD. A total of 259 participants with CeD were included in the studies investigating insomnia and 179 were included in studies investigating cognitive impairment. The overall pooled odds ratio for insomnia in patients with CeD was 1.83 (95% confidence interval, 1.38 to 2.42; I2=0.00%). The present study provides valuable insights into the available evidence from studies investigating cognitive impairment in patients with CeD and our systematic review and meta-analysis revealed a significant association between CeD and insomnia.
  • Thumbnail Image
    Item
    Pancreatic enzyme supplementation versus placebo for improvement of gastrointestinal symptoms in non-responsive celiac disease: A cross-over randomized controlled trial
    (Frontiers Media, 2023-01-04) Yoosuf, Shakira; Barrett, Caitlin G.; Papamichael, Konstantinos; Madoff, Sarah E.; Kurada, Satya; Hansen, Joshua; Silvester, Jocelyn A.; Therrien, Amelie; Singh, Prashant; Dennis, Melinda; Leffler, Daniel A.; Kelly, Ciaran P.; Medicine, School of Medicine
    Background: Pancreatic Exocrine Insufficiency (PEI) is a possible cause of recurrent/persistent symptoms in celiac disease. Although pancreatic enzyme supplementation may be used to treat non-responsive celiac disease (NRCD) in clinical practice, clinical outcomes are variable and there is limited and low quality evidence to support this practice. The aim of this study was to assess the efficacy of pancreatic enzyme supplements (PES) for improvement of gastrointestinal symptoms in NRCD. Methods: Prospective, randomized, placebo-controlled, double-blind, cross-over trial in adults with NRCD examining Celiac Disease-Gastrointestinal Symptom Rating Scale (CeD-GSRS) scores on PES (pancrelipase co-administered with omeprazole) versus placebo (omeprazole only) during a 10-day treatment period. The study was registered under the clinical trials registry (https://clinicaltrials.gov/ number, NCT02475369) on 18 Jun 2015. Results: Twelve participants (nine female) were included in the per-protocol analysis; one participant had low fecal elastase-1. Pancrelipase was not associated with significant change in CeD-GSRS compared to placebo (-0.03 versus -0.26; P = 0.366). There was a significant decrease in mean values of total CeD-GSRS scores (3.58 versus 2.90, P = 0.004), abdominal pain (2.92 versus 2.42, P = 0.009), and diarrhea sub-scores (3.44 versus 2.92, P = 0.037) during the run-in period with omeprazole. Conclusion: In this prospective, cross-over randomized, placebo-controlled study, PES did not improve symptoms in patients with NRCD. It is unclear whether this is a trial effect or related to administration of omeprazole.